Name: | adalimumab |
---|---|
PubChem Substance ID: | 3820740 |
Synonyms: |
331731-18-1; Humira; Immunoglobulin G1, anti-(human tumor necrosis factor) (human monoclonal D2E7 heavy chain), disulfide with human monoclonal D2E7 light chain, dimer; Adalimumab; Adalimumab [USAN]; D2E7
|
Name: | adalimumab |
---|---|
Name (isomeric): | DB00051 |
Drug Type: | biotech |
Synonyms: |
Ig gamma-1 chain C region
|
Brand: | Humira, Humira Pen, Humira (Abbott Laboratories) |
Category: | Immunomodulatory Agents, Antirheumatic Agents |
CAS number: | 331731-18-1 |
Indication: | For treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and Crohn's disease. |
---|---|
Pharmacology: | Used in the treatment of immune system mediated diseases, adalimumab binds specifically to TNF-alpha and blocks its general cytokine effects, thereby reducing TNF-induced inflammation and halting tissue destruction. |
Mechanism of Action: | Adalimumab binds to TNF-alpha and blocks its interaction with the p55 and p75 cell surface TNF receptors. Adalimumab also lyses surface TNF expressing cells in vitro in the presence of complement. |
Biotransformation: | Most likely removed by opsonization via the reticuloendothelial system. |
Half Life: | 10-20 days. |
Clearance: | 12 mL/hr [RA patients with dose 0.25-10 mg/kg] |
Affected organisms: | Humans and other mammals |
Drug interaction: |
|
---|